<VariationArchive VariationID="1708506" VariationName="NM_000069.3(CACNA1S):c.1252_1253del (p.Asn418fs)" VariationType="Deletion" Accession="VCV001708506" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2022-10-08" MostRecentSubmission="2022-10-08">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1706804" VariationID="1708506">
      <GeneList>
        <Gene Symbol="CACNA1S" FullName="calcium voltage-gated channel subunit alpha1 S" GeneID="779" HGNC_ID="HGNC:1397" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>1q32.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="201039512" stop="201112426" display_start="201039512" display_stop="201112426" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="201008639" stop="201081693" display_start="201008639" display_stop="201081693" Strand="-" />
          </Location>
          <OMIM>114208</OMIM>
          <Haploinsufficiency last_evaluated="2016-01-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CACNA1S">No evidence available</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2016-01-18" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CACNA1S">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000069.3(CACNA1S):c.1252_1253del (p.Asn418fs)</Name>
      <CanonicalSPDI>NC_000001.11:201083301:TT:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>1q32.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="1" Accession="NC_000001.11" start="201083302" stop="201083303" display_start="201083302" display_stop="201083303" variantLength="2" positionVCF="201083301" referenceAlleleVCF="GTT" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="1" Accession="NC_000001.10" start="201052430" stop="201052431" display_start="201052430" display_stop="201052431" variantLength="2" positionVCF="201052429" referenceAlleleVCF="GTT" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>N418fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.10" sequenceAccession="NC_000001" sequenceVersion="10" change="g.201052430_201052431del" Assembly="GRCh37">
            <Expression>NC_000001.10:g.201052430_201052431del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000001.11" sequenceAccession="NC_000001" sequenceVersion="11" change="g.201083302_201083303del" Assembly="GRCh38">
            <Expression>NC_000001.11:g.201083302_201083303del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009816.2" sequenceAccession="NG_009816" sequenceVersion="2" change="g.34264_34265del">
            <Expression>NG_009816.2:g.34264_34265del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000069.3" sequenceAccession="NM_000069" sequenceVersion="3" change="c.1252_1253del" MANESelect="true">
            <Expression>NM_000069.3:c.1252_1253del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000060.2" sequenceAccession="NP_000060" sequenceVersion="2" change="p.Asn418fs">
            <Expression>NP_000060.2:p.Asn418fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000069.3(CACNA1S):c.1252_1253del (p.Asn418fs) AND Malignant hyperthermia, susceptibility to, 5" Accession="RCV002287877" Version="3">
        <ClassifiedConditionList TraitSetID="5783">
          <ClassifiedCondition DB="MedGen" ID="C1866077">Malignant hyperthermia, susceptibility to, 5</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-09-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-09-27" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-10-08" MostRecentSubmission="2022-10-08">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="5783" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5445" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Malignant hyperthermia susceptibility type 5</ElementValue>
                <XRef ID="Malignant+hyperthermia+susceptibility+type+5/4430" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant hyperpyrexia susceptibility type 5</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Malignant hyperthermia, susceptibility to, 5</ElementValue>
                <XRef ID="MONDO:0011163" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MHS5</ElementValue>
                <XRef ID="GTR000557682" DB="Genetic Testing Registry (GTR)" />
                <XRef Type="MIM" ID="601887" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Pharmacogenetic</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Malignant hyperthermia susceptibility (MHS) is a pharmacogenetic disorder of skeletal muscle calcium regulation associated with uncontrolled skeletal muscle hypermetabolism. Manifestations of malignant hyperthermia (MH) are precipitated by certain volatile anesthetics (i.e., halothane, isoflurane, sevoflurane, desflurane, enflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine). The triggering substances cause uncontrolled release of calcium from the sarcoplasmic reticulum and may promote entry of extracellular calcium into the myoplasm, causing contracture of skeletal muscles, glycogenolysis, and increased cellular metabolism, resulting in production of heat and excess lactate. Affected individuals experience acidosis, hypercapnia, tachycardia, hyperthermia, muscle rigidity, compartment syndrome, rhabdomyolysis with subsequent increase in serum creatine kinase (CK) concentration, hyperkalemia with a risk for cardiac arrhythmia or even cardiac arrest, and myoglobinuria with a risk for renal failure. In nearly all cases, the first manifestations of MH (tachycardia and tachypnea) occur in the operating room; however, MH may also occur in the early postoperative period. There is mounting evidence that some individuals with MHS will also develop MH with exercise and/or on exposure to hot environments. Without proper and prompt treatment with dantrolene sodium, mortality is extremely high.</Attribute>
                <XRef ID="NBK1146" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3367" />
                <XRef ID="3367" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="EMHG, 2018">
                <ID Source="PubMed">33131754</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301325</ID>
                <ID Source="BookShelf">NBK1146</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_MalignantHyperthermia-enPro649.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Malignant hyperthermia</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Malignant-Hyperthermia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, RYR1 and CACNA1S Pathogenic Variants (Malignant Hyperthermia), 2019</CitationText>
              </Citation>
              <XRef ID="423" DB="Orphanet" />
              <XRef ID="C1866077" DB="MedGen" />
              <XRef ID="MONDO:0011163" DB="MONDO" />
              <XRef Type="MIM" ID="601887" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5039776" SubmissionDate="2022-10-07" DateLastUpdated="2022-10-08" DateCreated="2022-10-08">
        <ClinVarSubmissionID localKey="14c7911b-3663-4fef-a190-9569d2ca2026" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002578171" DateUpdated="2022-10-08" DateCreated="2022-10-08" Type="SCV" Version="1" SubmitterName="Institute for Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin" OrgID="505735" OrganizationCategory="clinic" OrgAbbreviation="Charité - Universitätsmedizin" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="507461" SubmitterName="CUBI - Core Unit Bioinformatics, Berlin Institute of Health" Type="secondary" OrganizationCategory="laboratory" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-09-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Tissue>Blood</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
              <FamilyData PedigreeID="077d08cd-707d-47aa-a690-f8d843d6e815" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SampleLocalID">4113f800-c1ab-4cf0-80d7-52ad4279dd1a</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CACNA1S" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="1" alternateAllele="G" referenceAllele="GTT" start="201052429" stop="201052431" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="601887" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB7643814</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5039776" TraitType="Disease" MappingType="XRef" MappingValue="601887" MappingRef="OMIM">
        <MedGen CUI="C1866077" Name="Malignant hyperthermia, susceptibility to, 5" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

